Information  X 
Enter a valid email address

Reckitt Benckiser Gp (RB.)

  Print          Annual reports

Thursday 17 December, 2020

Reckitt Benckiser Gp

Directorate Change

RNS Number : 0065J
Reckitt Benckiser Group PLC
17 December 2020


RB announces appointment of Olivier Bohuon as non-executive director

December 17, 2020, Slough UK - Reckitt Benckiser Group plc today announces the appointment of Olivier Bohuon to the Board as a non-executive director, effective January 1st, 2021. He will also join the Remuneration Committee on the same date.

Mr Bohuon was CEO of FTSE 100 medical devices company Smith & Nephew from 2011 to 2018.  Prior to that role he served as CEO of healthcare, cosmetology and pharmaceutical company Laboratoires Pierre Fabre from 2010-2011.  Before that he worked for Abbott Laboratories from 2003 to 2010, rising to corporate executive vice president and president of the pharmaceutical products division.  Mr Bohuon previously worked at GlaxoSmithKline plc for a number of years in positions of increasing seniority.

Mr Bohuon is a member of the supervisory board of Virbac SA, is Chairman of the Board of Directors of Leo Pharma in Denmark and serves on the Board of Takeda Pharmaceuticals in Japan.  He also served on the Board of Smiths Industries from July 2018 to November 2020.

Mr Bohuon is a member of the National Pharmacy Academy and the Academy of Technologies.  He became a Knight of the Legion of Honour in 2007.  He has a doctorate in pharmacy from University of Paris-Sud and MBA from HEC Paris.

Commenting on the appointment, Chris Sinclair, Chairman of the Board said:

"I am delighted that Olivier has agreed to join the Board.  He is a successful leader, with many years of experience as CEO of a large global company.  Olivier has deep experience in healthcare products and markets and will bring great insight to the Board and we welcome his appointment."

The Company confirms that there is no further information to be disclosed under the requirements of Listing Rule 9.6.13R in relation to Olivier Bohuon's appointment.


About RB

RB* is driven by its purpose to protect, heal and nurture in a relentless pursuit of a cleaner, healthier world. We fight to make access to the highest-quality hygiene, wellness and nourishment a right, not a privilege, for everyone.

RB is proud to have a stable of trusted household brands found in households in more than 190 countries. These include Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Woolite, Air Wick and more.  20 million RB products a day are bought by consumers globally.

RB's passion to put consumers and people first, to seek out new opportunities, to strive for excellence in all that we do, and to build shared success with all our partners, while doing the right thing, always is what guides the work of our 40,000+ diverse and talented colleagues worldwide. For more information visit

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

*RB is the trading name of the Reckitt Benckiser group of companies


For further information, please contact:

Reckitt Benckiser

Patty O'Hayer, James Fearnley-Marr

+44 (0)1753 217800


Faeth Birch

+44 (0)7768 943171


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t